Clinical Trial Results: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate lorundrostat added to SGLT2 inhibitors in patients with hypertension and chronic kidney disease with albuminuria; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Lorundrostat (lorundrostat)

Snippet

Sponsor: Mineralys Therapeutics Inc. | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-06-03